Biohackr.Labs

CUT Protocol

Retatrutide R50 Precision Start Pen

Eight weeks of precision-guided Retatrutide optimization.

Key Attributes

  • Complete 8-week Retatrutide onboarding in a single pen — no mid-protocol pen change
  • Triple-receptor agonist: simultaneous GLP-1, GIP, and glucagon activation
  • 200 precision clicks at 0.25 mg — full titration range covered
  • Most comprehensive Retatrutide starting protocol available in Bangkok and Thailand
  • European-sourced, cold-chain maintained, quality-controlled preparation

Technical Specifications

Total Content
50 mg Retatrutide
CAS Number
2381609-22-7
Fill Volume
2.0 mL
Concentration
25 mg/mL
Per Click
0.25 mg/click
Total Clicks
200
Collection
CUT
Shipping
Cold-chain delivery · 2–8°C
฿15,000THB
Enquire About This ProtocolBuild My Profile

Biohackr.Labs provides product education, protocol guidance, and private client support. Information on this website is not medical advice and does not replace consultation with a licensed healthcare professional.

Biohackr.Labs premium hard case open — precision pen and 10 individually sealed micro needles
Premium hard case open at angle — pen and needle kit in foam insert
Biohackr.Labs premium white hard case — closed with holographic logo

What's Included

Premium hard case.
Everything included.

Every Biohackr.Labs pen ships in our premium white hard case — holographic logo, foam-fitted interior. Inside: the precision pen, ten individually sealed 31G 8mm micro needles, and all documentation needed to begin your protocol correctly.

Precision pen

Pre-filled, batch quality-controlled pen system ready at your confirmed starting dose.

10× 31G micro needles

31G 8mm individually sealed sterile micro needles. Ten included as standard with every pen.

Protocol card

Starting dose, titration schedule, session guidance, and what to expect — specific to your protocol.

Batch QC documentation

Batch reference, preparation date, and compound specification. Not boilerplate — specific to your order.

Storage & handling guide

Temperature requirements, travel guidance, and handling notes with Bangkok climate context.

Private support access

WhatsApp, LINE, email, and My Account support throughout your protocol cycle.

Professional Packing

Strictly packed for
cold-chain delivery.

Peptide pen formulations are temperature-sensitive. Every order is packed as a refrigerated product and handled under strict cold-chain conditions — insulated temperature-control packaging with cold packs maintained at the standard refrigerated range of 2–8°C wherever available during transit.

Refrigerated cold-chain transport

Peptide pens are handled as refrigerated products throughout transit. Intended transport condition is controlled cold-chain delivery at 2–8°C wherever available. Available in supported cold-chain delivery areas only.

Temperature-control packaging

Insulated temperature-control packaging with cold packs engineered to maintain the product in the refrigerated range from preparation to handover — anywhere in Thailand with cold-chain delivery coverage.

Refrigerate immediately on receipt

Transfer to refrigerated storage the moment you receive your order. Do not leave unattended or delay collection. Tamper-evident sealing confirms product integrity at handover.

Biohackr.Labs temperature-controlled packaging — kraft shipping box open with insulated liner and sealed product inside
Biohackr.Labs temperature-controlled outer shipping box
Biohackr.Labs individually sealed product bag
Biohackr.Labs packaging components — thermal liner, insulated bag, sealed product
Biohackr.Labs product in premium sealed shipping bag

Step 01

Protocol Overview

“Eight weeks of precision-guided Retatrutide optimization.”

The R50 Precision Start Pen delivers 50 mg of Retatrutide across a complete 8-week guided onboarding protocol — the full arc from first dose to established metabolic response. With 200 precision clicks at 0.25 mg each, the R50 provides the volume needed to titrate through the early dose range, identify your individual response threshold, and enter a stable maintenance phase. The preferred starting pen for clients who want a structured full-course experience from the outset.

Step 02

Mechanism of Action

Retatrutide's triple-receptor activity (GLP-1, GIP, glucagon) produces progressive metabolic adaptation over the course of an 8-week protocol. The first 2–4 weeks typically establish appetite regulation; weeks 4–8 typically show body composition changes as metabolic efficiency improves. The R50's 200-click volume allows for full titration from entry dose through to an individual's established dose without interruption between pens.

Suggested Use

One weekly subcutaneous administration. Begin titration from 0.5 mg in week one and increase as guided. Full protocol guidance provided through order review.

Who This Protocol Is For

For clients in Bangkok and throughout Thailand seeking a complete, uninterrupted 8-week Retatrutide protocol from a single pen. Suitable for those who prefer a structured long-form approach and plan to transition to maintenance dosing after completing the onboarding arc.

Storage — Bangkok & Thailand

Refrigerate between 2–8°C. Thailand's heat accelerates peptide degradation — refrigeration is non-negotiable for a pen you will use over 8 weeks. Keep sealed until first use.

Delivery — Thailand

Peptide pens are shipped under strict cold-chain handling — handled as refrigerated products at 2–8°C wherever available. Available in supported cold-chain delivery areas only.

Refrigerate immediately on receipt. You must be present to receive the delivery directly.

Potential Side Effects

  • GI effects (nausea, vomiting, diarrhoea) — most common; dose-dependent and typically improve with careful titration
  • Reduced appetite — expected mechanism effect; can be significant at therapeutic doses
  • Injection site reactions — transient redness or discomfort at administration site
  • Fatigue — reported during dose escalation phases
  • Dysesthesia (tingling or altered skin sensation) — observed in approximately 21% of participants at 12 mg in Phase 3 trial data
  • Cardiac effects under active investigation in ongoing Phase 3 trials — prior medical suitability review required

Science Hub

Retatrutide: The First Triple AgonistThe TRIUMPH Program: Clinical Evidence for RetatrutideGLP-1, GIP, and Glucagon: The Triple Mechanism Explained

Order Review Required

All Biohackr.Labs orders are reviewed before confirmation. Dosing and administration are confirmed before fulfilment where required.

Enquire on WhatsAppAdd LINE

The Compound

What Is Retatrutide?

Retatrutide (LY3437943) is a synthetic once-weekly peptide developed by Eli Lilly — the first triple hormone receptor agonist to enter Phase 3 clinical trials. Where semaglutide activates one receptor and tirzepatide activates two, retatrutide simultaneously activates three: GLP-1, GIP, and glucagon. This triple mechanism produces compounding effects on appetite, fat metabolism, and energy expenditure that neither dual nor single agonists can replicate.

By targeting three complementary metabolic pathways at once, retatrutide addresses the biology of excess weight from multiple angles simultaneously. The result is weight loss outcomes that exceed what single or dual agonist compounds can achieve — including outcomes comparable to bariatric surgery in a subset of patients.

Semaglutide

Ozempic / Wegovy

1 receptor

Mechanism

GLP-1 only

Peak weight loss

~13.9%

Tirzepatide

Mounjaro / Zepbound

2 receptors

Mechanism

GLP-1 + GIP

Peak weight loss

~17.8–20.9%

Retatrutide

Pending (LY3437943)

3 receptors

Mechanism

GLP-1 + GIP + Glucagon

Peak weight loss

~28.3–30.3%

Cross-trial comparisons have inherent limitations. A head-to-head trial would be required for definitive conclusions.

Triple Mechanism

What Each Agonist Does

GLP-1

Glucagon-Like Peptide-1

Role

Appetite and insulin regulation

Slows gastric emptying to reduce caloric intake, suppresses appetite signals in the hypothalamus, and stimulates glucose-dependent insulin secretion. GLP-1 agonism is the foundation of semaglutide and tirzepatide — and the primary mechanism of all incretin-based compounds.

Key Effect

Appetite reduction + insulin sensitivity

Also in: Semaglutide, Tirzepatide

GIP

Glucose-dependent Insulinotropic Polypeptide

Role

Nutrient partitioning and fat cell metabolism

Enhances insulin sensitivity in peripheral tissues, modulates how the body partitions incoming calories between storage and use, and appears to amplify the appetite-suppressing effects of GLP-1 agonism. GIP is the second receptor targeted by tirzepatide — and a key contributor to its weight loss advantage over semaglutide.

Key Effect

Enhanced insulin sensitivity + fat cell regulation

Also in: Tirzepatide

Glucagon

Glucagon Receptor

Role

Energy expenditure and direct liver fat clearance

The critical differentiator. Glucagon receptor activation directly stimulates the liver to burn stored fat (fatty acid oxidation) and suppresses new fat synthesis (de novo lipogenesis). It also increases basal metabolic rate and thermogenesis — meaning the body burns more calories at rest. No approved obesity medication targets this receptor. It is the mechanism responsible for retatrutide's unprecedented liver fat reduction data.

Key Effect

Increased energy expenditure + hepatic fat clearance

Also in: Unique to Retatrutide among approved/late-stage compounds

Beyond Weight Loss

Emerging Benefits From Clinical Data

Clinical trial data surfacing across the TRIUMPH program suggests retatrutide may offer systemic benefits beyond weight management — driven by the glucagon receptor component that neither semaglutide nor tirzepatide possess.

Metabolic Liver Disease (MASLD/MASH)

The glucagon receptor component drives direct hepatic fat oxidation — the liver burns its stored triglycerides. Phase 2a data (Nature Medicine, 2024) showed 82.4% liver fat reduction and more than 85% liver fat normalization at the 12 mg dose. Phase 3 MASLD/MASH-specific trials are underway.

Knee Osteoarthritis

TRIUMPH-1 reported a nested knee osteoarthritis basket trial, with WOMAC pain scores reduced by up to 4.3 points (73.1%) at 80 weeks. TRIUMPH-4 remains the dedicated knee osteoarthritis study in the registry.

Systemic Inflammation

TRIUMPH-1 investigators noted "clear improvements in assessed cardiometabolic health measures" including inflammatory markers. The triple receptor mechanism appears to address metabolic inflammation through multiple pathways — weight-independent of the pure weight loss effect.

Insulin Resistance

TRIUMPH-2 topline data in adults with type 2 diabetes and obesity or overweight reported up to 20.8% mean weight loss and A1C reductions of up to 1.6 percentage points over 80 weeks.

Sleep Apnoea

TRIUMPH-1 reported a nested moderate-to-severe obstructive sleep apnoea basket trial, with apnea-hypopnea index reduced by up to 36.1 events per hour (60.6%) at 80 weeks.

Cardiovascular Outcomes

TRIUMPH-3 reported up to 22.6% mean weight loss at 80 weeks in adults with severe obesity and established cardiovascular disease. Its pre-specified cardiovascular event analyses were underpowered and inconclusive, so the dedicated TRIUMPH-Outcomes study remains the key cardiovascular and kidney outcomes trial.

All emerging benefit data is from Phase 2 or Phase 3 clinical trial publications and official Eli Lilly announcements. Retatrutide is investigational. Benefits described are not confirmed clinical indications.

Live Research

TRIUMPH Trial Tracker

Last updated

October 4, 2026

Eli Lilly TRIUMPH Phase 3 · published highlights + active registry watch

TRIUMPH-1Adults with obesity without diabetes (n=2,339)
Peer-reviewed: NEJMSeptember 29, 2026

Stomach and bowel side effects were most common. Altered skin sensation and stopping treatment due to side effects were also reported.

TRIUMPH-1 source

TRIUMPH-1: results, safety and sources

At 80 weeks, peer-reviewed treatment-regimen/ITT mean weight change: −17.6% (4 mg), −23.7% (9 mg), −25.0% (12 mg) versus −3.9% placebo. Earlier Lilly efficacy-estimand headline: −28.3% (12 mg) versus −2.2% placebo at 80 weeks (70.3 lbs mean loss); 45.3% achieved ≥30% weight loss in that efficacy analysis. Lilly reported 30.3% mean loss at 104 weeks only in the selected baseline BMI ≥35 completers who tolerated treatment and continued on 12 mg in the prespecified extension.

Safety: Gastrointestinal adverse events were most common. Lilly’s June release reported dysesthesia (altered skin sensation) in 12.5% with 12 mg versus 0.9% placebo, and adverse-event discontinuation in 11.3% versus 4.9%, respectively.

NEJM TRIUMPH-1 publicationLilly TRIUMPH-1 80-week efficacy estimandLilly TRIUMPH-1 efficacy estimand and safety

TRIUMPH-2Adults with overweight/obesity and type 2 diabetes (n=1,152)
Peer-reviewed: The LancetSeptember 29, 2026

Stomach and bowel side effects were most common. Altered skin sensation, low blood pressure, and stopping treatment due to side effects were also reported.

TRIUMPH-2 source

TRIUMPH-2: results, safety and sources

At 80 weeks, peer-reviewed treatment-regimen mean weight change: −11.9% (4 mg), −16.8% (9 mg), −18.8% (12 mg) versus −5.1% placebo. Lilly’s separate efficacy-estimand headline: −20.8% (12 mg) versus −4.0% placebo at 80 weeks; A1C reduction up to 1.6 percentage points.

Safety: Gastrointestinal adverse events were most common; hypotension and dysesthesia were more frequent than with placebo. Lilly’s September release reported dysesthesia in 7.3% with 12 mg versus 0.7% placebo, and adverse-event discontinuation in 7.7% versus 4.9%, respectively. The Lancet separately reported discontinuation due to adverse events or death: 8% (12 mg) versus 5% placebo.

The Lancet TRIUMPH-2 publication (PubMed)Lilly TRIUMPH-2 efficacy estimand and safety

TRIUMPH-3Established cardiovascular disease
Sponsor results reportedJuly 2026 topline readout; registry completed Jul 2026

TRIUMPH-3 source

TRIUMPH-3: results and sources

Topline Lilly readout: up to 22.6% mean weight loss at 80 weeks; cardiovascular event analyses were inconclusive because event rates were lower than expected.

TRIUMPH-4Obesity with knee osteoarthritis
Sponsor results reportedDec 2025

TRIUMPH-4 source

TRIUMPH-4: results and sources

28.7% avg weight loss at 68 weeks (12 mg). Substantial knee pain reduction.

TRIUMPH-OutcomesCardiovascular and kidney outcomes
ActiveRegistry updated September 24, 2026

TRIUMPH-Outcomes source

TRIUMPH-Outcomes: results and sources

Large event-driven Phase 3 outcomes study; ClinicalTrials.gov lists estimated completion in 2029.

How to read the results

Treatment-regimen analyses include outcomes regardless of treatment discontinuation; ITT means intention-to-treat. The efficacy estimand estimates outcomes assuming participants remained on treatment without prohibited weight-management treatments. These analyses and the selected extension population are not interchangeable, and trial results do not establish outcomes for Biohackr.Labs pens.

Retatrutide remains investigational and is not approved by any regulatory agency. Lilly plans a U.S. submission in Q1 2027; this is not an approval date. · ClinicalTrials.gov API checked October 4, 2026; TRIUMPH-Outcomes active, not recruiting, with estimated completion in February 2029. Review monthly, and immediately after Lilly readouts or registry updates. Data is reviewed against official registries, Eli Lilly releases, and peer-reviewed publications. Retatrutide is investigational and not approved for clinical use.

Key Statistics

Retatrutide Research Highlights

25.0%

TRIUMPH-1 mean weight loss at 80 weeks

Adults with obesity without diabetes; 12 mg vs 3.9% placebo, treatment-regimen/ITT analysis

NEJM, September 29, 2026

18.8%

TRIUMPH-2 mean weight loss at 80 weeks

Adults with overweight/obesity and type 2 diabetes; 12 mg vs 5.1% placebo, treatment-regimen analysis

The Lancet, September 29, 2026

30.3%

Selected TRIUMPH-1 extension at 104 weeks

Lilly efficacy estimand, 12 mg; baseline BMI ≥35 completers who tolerated treatment and continued into the prespecified extension. Not the overall 80-week result

Eli Lilly, June 2026

82.4%

Mean relative liver fat reduction at 24 weeks

12 mg, Phase 2a MASLD substudy (n=98), efficacy estimand. Mean relative change from baseline: −82.4% at week 24; −86.0% at week 48. Only 43.9% of substudy participants had week-48 MRI data

Nature Medicine, 2024 (PMID 38858523)

86%

Participants achieving normal liver fat at 24 weeks

Normal liver fat (<5%), 12 mg, Phase 2a MASLD substudy, efficacy estimand: 86% at week 24; 93% at week 48. Only 43.9% of substudy participants had week-48 MRI data

Nature Medicine, 2024 (PMID 38858523)

5,800+

Participants enrolled in TRIUMPH program

Across four global registrational trials — the largest retatrutide trial program to date

Eli Lilly, 2026

Same Collection

Related CUT Protocols

Retatrutide R25 Fast Start Pen

CUT

Retatrutide R25 Fast Start Pen

฿8,500

View details →

Retatrutide R40 Maintenance Pen

CUT

Retatrutide R40 Maintenance Pen

฿12,000

View details →

My Account

Premium imported peptide pens in Bangkok.

Reviewed My Account ordering · European-sourced · Quality-controlled · Thailand delivery

Enquire About Retatrutide R50 Precision Start Pen